Format

Send to

Choose Destination
Lancet. 2000 Dec 2;356(9245):1902-3.

Can measurements of IGF-1 and IGFBP-3 improve the sensitivity of prostate-cancer screening?

Abstract

Further well designed studies are urgently needed to clarify if use of prostate-specific antigen (PSA) as a diagnostic test for prostate cancer can be improved by incorporating measurements of serum insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding-protein 3 (IGFBP-3), and if these measurements might also identify men at higher risk.

Comment in

PMID:
11130391
DOI:
10.1016/S0140-6736(00)03266-9
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center